Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Helus Pharma ( (HELP) ) has issued an announcement.
On April 30, 2026, Helus Pharma announced a collaboration with mental health organization TARA Mind to bolster recruitment for its PARADIGM HLP003 Phase 3 trial in major depressive disorder and deepen outreach to U.S. veterans, a population facing elevated rates of depression, PTSD and suicide. The initiative is positioned as a direct response to President Trump’s April 18, 2026 Executive Order on accelerating breakthrough mental health treatments, underscoring Helus Pharma’s push to align its FDA Breakthrough Therapy‑designated program with national priorities in veteran mental healthcare and to strengthen its standing in the emerging NSA-based depression treatment market.
TARA Mind will leverage its clinician-guided, data-driven collaborative care platform and veteran networks to engage participants and raise awareness of cutting-edge clinical opportunities, potentially improving trial enrollment and real-world relevance for HLP003. By anchoring its clinical development strategy in veteran needs and high-profile policy momentum, Helus Pharma aims to advance patient-centric innovation in serious mental illness while enhancing its profile among regulators, clinicians and stakeholders seeking more durable solutions for treatment-resistant mental health disorders.
The most recent analyst rating on (HELP) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on Helus Pharma stock, see the HELP Stock Forecast page.
More about Helus Pharma
Helus Pharma, the commercial name of Cybin Inc., is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways and promote neuroplasticity for mental health conditions. The company’s lead candidate HLP003 is in Phase 3 as an adjunctive treatment for major depressive disorder with U.S. FDA Breakthrough Therapy designation, alongside HLP004 in Phase 2 for generalized anxiety disorder, supported by an extensive NSA research portfolio across Canada, the U.S., the U.K. and Ireland.
Average Trading Volume: 1,180,691
Technical Sentiment Signal: Sell
Current Market Cap: $1.41M
For detailed information about HELP stock, go to TipRanks’ Stock Analysis page.